Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide

Journal of Immunology

Volumn 167, Issue 3, 2001, Pages 1609-1616

  Abreu, M T ^a   Vora, P ^a   Faure, E ^a   Thomas, L S ^a   Arnold, E T ^a   Arditi, M ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 8; PROTEIN MD 2; RECEPTOR; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ARTICLE; CELL PROTECTION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN CELL; INFLAMMATION; INTESTINE EPITHELIUM CELL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

EID: 0035424901     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.3.1609     Document Type: Article

References (74)

1. Innate mechanisms of epithelial host defense: Spotlight on intestine
2. Review article: Pathobiology of neutrophil interactions with intestinal epithelia
3. Apoptosis of human intestinal epithelial cells after bacterial invasion
4. Probiotic spectra of lactic acid bacteria (LAB)
5. Probiotics and inflammatory bowel diseases
6. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats
7. Bacterial regulation of intestinal immune responses
8. Microbe-host interactions in the alimentary tract: The gateway to understanding inflammatory bowel disease
9. Pharmacotherapy for inducing and maintaining remission in pouchitis
10. Probiotics in chronic pouchitis: Restoring luminal microbial balance
11. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial
12. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial
13. An antibiotic regimen for the treatment of active Crohn's disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacin
14. Antibacterial therapy for Crohn's disease: A review emphasizing therapy directed against mycobacteria
15. Innate immunity
16. Toll-like receptors in the induction of the innate immune response
17. Tlr4: Central component of the sole mammalian LPS sensor
18. Toll receptors: An expanding role in our understanding of human disease
19. A family of human receptors structurally related to Drosophila Toll
20. Cloning and characterization of a subfamily of human Toll-like receptors: hTLR7, hTLR8 and hTLR9
21. A Toll-Iike receptor recognizes bacterial DNA
22. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction
23. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide
24. Bacterial lipopolysaccharide activates NF-κB through Toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells: Differential expression of TLR-4 and TLR-2 in endothelial cells
25. CD14, new aspects of ligand and signal diversity
26. Regulatory roles for CD14 and phosphatidylinositol in the signaling via Toll-like receptor 4-MD-2
27. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4
28. Cutting edge: Cell surface expression and lipopolysaccharide signaling via the Toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages
29. Cellular events mediated by lipopolysaccharide-stimulated Toll-like receptor 4: MD-2 is required for activation of mitogen-activated protein kinases and EIk-1
30. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene
31. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages
32. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2
33. Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors
34. Bacterial lipopolysaccharide activates nuclear factor-κB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes
35. Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: Selective expression of TLR3 in dendritic cells
36. Differential cytokine expression by human intestinal epithelial cell lines: Regulated expression of interleukin 8
37. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion
38. Colonic epithelial cell lines as a source of interleukin-8: Stimulation by inflammatory cytokines and bacterial lipopolysaccharide
39. Attachment of a noninvasive enteric pathogen, enteropathogenic Escherichia coli, to cultured human intestinal epithelial monolayers induces transmigration of neutrophils
40. Activation of NF-κB in intestinal epithelial cells by enteropathogenic Escherichia coli
41. Colonic epithelial cell lines as a source of interleukin-8: Stimulation by inflammatory cytokines and bacterial lipopolysaccharide
42. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors
43. Cellular differentiation causes a selective down-regulation of interleukin (IL)-1β-mediated NF-κB activation and IL-8 gene expression in intestinal epithelial cells
44. NF-κB is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria
45. Epithelial cells secrete the chemokine interleukin-8 in response to bacterial entry
46. Cutting edge: Repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2
47. Modulation of barrier function during Fas-mediated apoptosis in human intestinal epithelial cells
48. A human colonic tumor cell line that maintains vectorial electrolyte transport
49. HMEC-1: Establishment of an immortalized human microvascular endothelial cell line
50. Chemical, physical, biological properties of a lipopolysaccharide from Escherichia coli K-235
51. Novel method for the purification and characterization of lipopolysaccharide from Escherichia coli D31m3
52. Inhibition of macrophage tumoricidal activity by glucocorticoids
53. Lipid A-associated proteins provide an alternate "second signal" in the activation of recombinant interferon-γ-primed, C3H/HeJ macrophages to a fully tumoricidal state
54. Mitogen-activated protein kinase kinase kinase I activates androgen receptor-dependent transcription and apoptosis in prostate cancer
55. Transcription factors NF-IL6 and NF-κB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8
56. MyD88 is ah adaptor protein in the hToll/IL-1 receptor family signaling pathways
57. MD-2 functionally complements a mutant LPS non-responder CHO/CD14 cell line
58. Analysis of Tlr4-mediated LPS signal transduction in macrophages by mutational modification of the receptor
59. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases
60. The influence of normal microbial flora on the development of chronic mucosal inflammation
61. The role of the Lps gene in experimental ulcerative colitis in mice
62. Mucosal biopsy diagnosis of colitis: Acute self-limited colitis and idiopathic inflammatory bowel disease
63. Dose-response relationship to inhaled endotoxin in normal subjects
64. Immunoregulatory potential of urothelium: Characterization of NF-κB signal transduction
65. Characterization of interleukin-1 receptor-associated kinase in normal and endotoxin-tolerant cells
66. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans
67. n gene: In vivo evidence for a dominant negative mutation
68. A46R and A52R from vaccinia virus are antagonists of host IL-1 and Toll-like receptor signaling
69. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease
70. The IκB/NF-κB system: A key determinant of mucosalinflammation and protection
71. Cutting edge: Preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway
72. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors
73. Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis
74. Toll-like receptors confer responsiveness to lipopolysaccharide from Porphyromonas gingivalis in human gingival fibroblasts